![Claes Lindblad](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Claes Lindblad
Directeur Financier/CFO chez
MODUS THERAPEUTICS HOLDING AB
Profil
Claes Lindblad is currently Chief Financial Officer & Head-Investor Relations at Modus Therapeutics Holding AB since 2021.
Formerly, Mr. Lindblad was Manager-National Sales at Nycomed AB from 2009 to 2012, Country Manager at ConvaTec (Sweden) AB from 2012 to 2016, and Chief Financial Officer & Secretary at OssDsign AB from 2016 to 2020.
Education includes a graduate degree from Karlstad University and an MBA from Edinburgh Business School.
Postes actifs de Claes Lindblad
| Sociétés | Poste | Début |
|---|---|---|
| MODUS THERAPEUTICS HOLDING AB | Directeur Financier/CFO | 15/03/2021 |
Anciens postes connus de Claes Lindblad
| Sociétés | Poste | Fin |
|---|---|---|
| OSSDSIGN AB | Directeur Financier/CFO | 01/01/2020 |
ConvaTec (Sweden) AB | Directeur/Membre du Conseil | 01/03/2016 |
Nycomed AB
 Nycomed AB Pharmaceuticals: MajorHealth Technology Provides medicines and products for hospitals, specialists and general practitioners | Sales & Marketing | 01/07/2012 |
Formation de Claes Lindblad
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Karlstad University
 Karlstad University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nycomed AB
Nycomed AB Pharmaceuticals: MajorHealth Technology Provides medicines and products for hospitals, specialists and general practitioners | Health Technology |
ConvaTec (Sweden) AB | |
OssDsign AB
 OssDsign AB Medical SpecialtiesHealth Technology Designs, manufactures and markets implants for healing and treatment of bone defects | Health Technology |
Modus Therapeutics Holding AB
 Modus Therapeutics Holding AB BiotechnologyHealth Technology Develops sevuparin to treat people suffering from sickle cell disease | Health Technology |
Edinburgh Business School
 Edinburgh Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
